Femasys Inc. (NASDAQ:FEMY – Get Rating)'s share price traded up 20.4% during trading on Monday . The stock traded as high as $1.24 and last traded at $1.18. 30,555 shares were traded during mid-day trading, an increase of 146% from the average session volume of 12,414 shares. The stock had previously closed at $0.98.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. Chardan Capital decreased their price target on Femasys from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 11th. HC Wainwright dropped their price objective on shares of Femasys from $8.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, October 20th.
Get
Femasys alerts:
Femasys Stock Up 20.4 %
The business's 50 day moving average is $1.12 and its 200-day moving average is $1.53. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.56 and a quick ratio of 9.37. The company has a market cap of $13.94 million, a PE ratio of -1.49 and a beta of -0.23.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Tri Locum Partners LP lifted its position in shares of Femasys by 27.2% during the 3rd quarter. Tri Locum Partners LP now owns 106,606 shares of the company's stock worth $120,000 after buying an additional 22,775 shares during the last quarter. Vanguard Group Inc. raised its position in Femasys by 15.1% in the 3rd quarter. Vanguard Group Inc. now owns 137,133 shares of the company's stock valued at $155,000 after purchasing an additional 17,948 shares during the last quarter. Virtu Financial LLC purchased a new stake in Femasys in the 2nd quarter valued at $39,000. LPL Financial LLC purchased a new stake in Femasys in the 2nd quarter valued at $51,000. Finally, CM Management LLC raised its position in Femasys by 33.3% in the 2nd quarter. CM Management LLC now owns 300,000 shares of the company's stock valued at $723,000 after purchasing an additional 75,000 shares during the last quarter. Hedge funds and other institutional investors own 7.49% of the company's stock.
Femasys Company Profile
(Get Rating)
Femasys Inc, a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing.
Further Reading
- Get a free copy of the StockNews.com research report on Femasys (FEMY)
- Why Wall Street Has Bullish Targets on Target Stock
- 3 Airline Stocks Taking Off in 2023
- What Macy's Guidance Means For Retail
- Fortinet Stock Price Bumpy, Here Is Why
- Apexigen Stock Soars After Analyst Rating, Is It Time to Buy?
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
